Asian Pacific Journal of Cancer Prevention · 2014 · 19 citations · 18 references
MedicineMolecular BiologyOncologyEpigeneticsMolecular OncologyOncogenesCancer BiomarkersCancer EpigenomicsEndometrial CancerEpigenetic Alterations In CancerMalignant NeoplasmsMolecular Tumor ProfilingCell Migration AnalysisDrug Target AlterationsEndometrial ProliferationHistone Demethylase InhibitionWestern Blotting
Previous studies have demonstrated that JMJD2A is a potential oncogene and is overexpressed in human tumors. However, its role in the endometrial carcinoma remains largely unknown. In this study, we discovered that JMJD2A was overexpressed in endometrial carcinoma, using immunohistochemistry, quantitative real- time polymerase chain reaction, and western blotting. Downregulation of JMJD2A led to reduced endometrial carcinoma RL95-2 and ISK cell proliferation, invasion and metastasis as asessed with cell counting kit-8, cell migration and invasive assays. Collectively, our results support that JMJD2A is a promoter of endometrial carcinoma cell proliferation and survival, and is a potential novel drug target.
18
Rebecca L. Siegel, Deepa Naishadham, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2013 · 11.9K citations · Full text
Histone demethylation by a family of JmjC domain-containing proteins
Yu-ichi Tsukada, Jia Fang, Hediye Erdjument‐Bromage et al. · Nature · 2005 · 2.1K citations
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Paul A. Cloos, Karl Agger, Alessio Maiolica et al. · Nature · 2006 · 749 citations
Georgios Lyratzopoulos, Richard D Neal, Josephine Barbiere et al. · The Lancet Oncology · 2012 · 421 citations · Full text